Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma.
Saved in:
| Title: | Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma. |
|---|---|
| Authors: | Faraoni EY; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Strickland LN; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., O'Brien BJ; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Barraza JF; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Thosani NC; Center for Interventional Gastroenterology at UTHealth (iGUT), McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Wray CJ; Department of Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Mills TW; Department of Biochemistry, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Bailey-Lundberg JM; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; Center for Interventional Gastroenterology at UTHealth (iGUT), McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; Department of Anesthesiology, Center for Perioperative Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2022 Sep 06; Vol. 12, pp. 995027. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36147911 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Faraoni+EY%22">Faraoni EY</searchLink>; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Strickland+LN%22">Strickland LN</searchLink>; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22O'Brien+BJ%22">O'Brien BJ</searchLink>; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Barraza+JF%22">Barraza JF</searchLink>; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Thosani+NC%22">Thosani NC</searchLink>; Center for Interventional Gastroenterology at UTHealth (iGUT), McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Wray+CJ%22">Wray CJ</searchLink>; Department of Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Mills+TW%22">Mills TW</searchLink>; Department of Biochemistry, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Bailey-Lundberg+JM%22">Bailey-Lundberg JM</searchLink>; Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; Center for Interventional Gastroenterology at UTHealth (iGUT), McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.; Department of Anesthesiology, Center for Perioperative Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2022 Sep 06; Vol. 12, pp. 995027. <i>Date of Electronic Publication: </i>2022 Sep 06 (<i>Print Publication: </i>2022). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36147911 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fonc.2022.995027 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 995027 Titles: – TitleFull: Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Faraoni EY – PersonEntity: Name: NameFull: Strickland LN – PersonEntity: Name: NameFull: O'Brien BJ – PersonEntity: Name: NameFull: Barraza JF – PersonEntity: Name: NameFull: Thosani NC – PersonEntity: Name: NameFull: Wray CJ – PersonEntity: Name: NameFull: Mills TW – PersonEntity: Name: NameFull: Bailey-Lundberg JM IsPartOfRelationships: – BibEntity: Dates: – D: 06 M: 09 Text: 2022 Sep 06 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 2234-943X Numbering: – Type: volume Value: 12 Titles: – TitleFull: Frontiers in oncology Type: main |
| ResultId | 1 |
